Towards a systematic scientific approach in the assessment of efficacy of an herbal preparation: Hawthorn (Crataegus spp.)

European Journal of Heart Failure

Volumn 10, Issue 12, 2008, Pages 1153-1157

  Furey, Ambrose ^a   Tassell, Mary ^a  

^a Munster Technological University   (Ireland)

Author keywords

Crataegus; Hawthorn; SPICE trial; Treatment

Indexed keywords

ALDOSTERONE; ARTEMISININ; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CATECHIN; CRATAEGUS EXTRACT; CYCLIC AMP; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPICATECHIN; FLAVONOID; GALANTAMINE; IVERMECTIN; PACLITAXEL; PENICILLIN G; PROCYANIDIN; RESERPINE; SENNOSIDE; TACROLIMUS;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DILATATION; CRATAEGUS; DRUG EFFICACY; DRUG STRUCTURE; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HERBAL MEDICINE; HUMAN; NOMENCLATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUDDEN DEATH;

CARDIOVASCULAR SYSTEM; CRATAEGUS; EVIDENCE-BASED MEDICINE; EXERCISE TOLERANCE; FLAVONOIDS; HERBAL MEDICINE; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 56349110985     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.10.003     Document Type: Editorial

References (38)

1. Palnoki O., and Jacomet S. Some aspects of Late Iron Age agriculture based on the first results of anarchaeobotanical investigation at Cprvin ter, Budapest, Hungary. Veg Hist Archaeobot 11 (2002) 9-15
2. Grattan J.H.G., and Singer C. Anglo-Saxon magic and medicine (1952), Oxford University Press, London
3. Gerard J. The herbal or general history of plants (1633), Dover Publications, New York
4. Allen D.E., and Hatfield G. Medicinal plants in folk tradition. An ethnobotany of Britain and Ireland (2004), Timber Press, Cambridge
5. C. Hobbs. Hawthorn for the heart. 199 [cited 2007 29/10]; Available from: http://www.healthy.net/scr/Article.asp?Id=898.
6. Hedley C. Humours, hearts and hawthorn. Eur J Herb Med 5 2 (1996) 27-31
7. Hall A., and Barker A. The national botanic pharmacopoeia (1932), The National Association of Medical Herbalists, Tunstall
8. Lyle T.J. Physio-medical therapeutics, materia medica and pharmacy (1932), National Association of Medical Herbalists, London
9. Mills S., and Bone K. Principles and practice of phytotherapy (2000), Churchill Livingstone, London
10. Murray M. The healing power of herbs (1995), Prima Publishing, Rocklin USA
11. Weiss R.F. Herbal medicine (1998), Beaconsfield Publishers Ltd, Beaconsfield
12. Krzeminshi T., and Chatterjee S.S. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha. L Pharm Pharmacol Lett 3 (1993) 45-48
13. Holusbarsch C.J.F., Collucci W.S., Meinertz T., Gaus W., and Tendera M. The efficacy and safety of Crataegus extract WS® 1442 in patients with heart failure: the SPICE trial. Eur J Heart Fail 10 12 (2008) 1255-1263
14. Pittler M.H., Guo R., and Ernst E. Hawthorn extract for treating chronic heart failure. Results studies Cochrane Database Syst Rev 1 (2008) CD005312
15. Zick S.M., Gillespie B., and Aaronson K. The effect of Crataegus oxyacantha special extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail 10 (2008) 587-593
16. Lalukota K., Cleland J.G.F., Ingle L., Clark A.L., and Coletta A.P. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. Eur J Heart Fail 6 7 (2004) 953-955
17. Svedstrom U., Vuorela H., Kostianien R., Laakso I., and Hiltunen R. Fractionation of polyphenols in hawthorn into polymeric procyanidins, phenolic acids and flavonoids prior to high-performance liquid chromatographic analysis. J Chromatogr 1112 (2006) 103-111
18. Fong H.H.S., and Bauman J.L. Hawthorn. J Cardiovasc Nurs 16 (2002) 1-8
19. Svedstrom U., Vuorela H., Kostiainen R., Huovinen K., Laakso I., and Hiltunen R. High-performance liquid chromatographic determinationof oligomeric procyanidins from dimers up to hexamer in hawthorn. J Chromatogr 968 1-2 (2002) 53-60
20. Long S.R., Carey R.A., Crofoot K.M., Proteau P.J., and Filtz T.M. Effect of hawthorn (Crataegus oxyacantha) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. Phytomedicine 13 (2006) 643-650
21. Zapatero J.M. Selections from current literature: effects of hawthorn on the cardiovascular system. Fam Pract 16 5 (1999) 534-538
22. Bahorun T., Aumjaud E., Ramphul H., Rycha M., Luximon-Ramma A., Trotin F., et al. Oxygen species scavenging activity of phenolic extracts from hawthorn fresh plant organs and pharmaceutical preparations. Arzneimittelforschung 46 (1996) 1086-1089
23. Sokol-Letowska A., Oszmianski J., and Wojdylo A. Antioxidant activity of the phenolic compounds of hawthorn, pine and skullcap. Food Chem 103 (2006) 853-859
24. Cirico T., and Omaye S.T. Additive or synergetic effects of phenolic compounds on human low density lipoprotein oxidation. Food Chem Toxicol 44 4 (2005) 510-516
25. Skegert M., Kotnik P., Hadolin, Hraz A., Simonic M., and Knez Z. Phenols, procyanidins, flavones and flavonols in some plant materials and their antioxidant activities. Food Chem 89 (2005) 191-198
26. Schroder D., Weiser M., and LKlein P. Efficacy of a homeopathic Crataegus preparation compared with usual therapy for mild (NYHA II) cardiac insufficiency: results of an observational cohort study. Eur J Heart Fail 5 (2002) 319-326
27. Asgary S., Naderi G., Sadeghi M., Kelishadi R., and Amiri M. Antihypertensive effect of Iranian Crataegus curvisepala Lind.: a randomized, double-blind study. Drugs Exp Clin Res 30 5-6 (2004) 221-225
28. Habs M. Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without hawthorn special extract WS 1442. Forschende Komplementarmedizin Klassische Naturheilkunde 11 Suppl1 (2004) 36-39
29. Pittler M.H., Schmidt K., and Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomised trials. Am J Med 114 (2003) 665-674
30. ESCOP. Expanded commision E monographs (1994)
31. Tauchert M. Efficacy and safety of Crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class III heart failure. Am Heart J 143 (2002) 910-915
32. Houlbarsch C., Colucci W., Meinertz T., Gaus W., and Tednera M. Survival and prognosis: investigation of Crataegus extract WS1442 in congestive heart failure (SPICE) - rationale, study design and study protocol. Eur J Heart Fail 2 4 (2000) 431-437
33. Brown D. High dose hawthorn extract for advanced congestive heart failure. Herbalgram 28 57 (2003) 24-25
34. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to Medicinal Products for Human Use. Official Journal L - 311 (28/11/2004) 67-128
35. Walker A., Simpson E., Hope J., Robinson P., Hassanein M., and Simpson H. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. British Journal of General Practice 56 (2005) 437-443
36. Degenring F., Suter A., Weber M., and Saller R. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine 10 (2003) 363-369
37. Zapfe G. Clinical efficacy of Crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine 8 (2001) 262-266
38. Hellenbrecht D., Saller R., Ruckbeil C., and Buhring M. Randomised, placebo controlled study with Crataegus on exercise tests and challenge by catecholamines. Eur J Pharmacol 183 (1990) 525-526